Subject
Cancer Research,Oncology,Oral Surgery
Reference32 articles.
1. Ferris RL, Jr GB, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
2. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019
3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019
4. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study;Gatta;Eur J Cancer,2015
5. European Medicines Agency. 2018. Assessment report. Invented name: Keytruda. Available from: https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0042-epar-assessment-report-variation_en.pdf. Accessed April 9, 2023.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献